DOCSLIB.ORG

Guidelines for Case Management of Malaria (2015)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidelines for Case Management of Malaria (2015) Government of Sierra Leone Ministry of Health and Sanitation National Malaria Control Programme Guidelines for Case Management of Malaria Fourth Edition 2015 1 | P a g e 2 | P a g e 3 | P a g e Table of Contents EXECUTIVE SUMMARY ................................................................................................................................................................ 6 1.0 INTRODUCTION .................................................................................................................................................................. 7 1.1 EPIDEMIOLOGICAL SITUATION AND PARASITE DISTRIBUTION ............................................................................. 7 1.2 NATIONAL DRUG RESISTANCE PATTERN ...................................................................................................................... 7 1.3 GENERAL OBJECTIVE .......................................................................................................................................................... 9 1.4 SPECIFIC OBJECTIVE ........................................................................................................................................................... 9 1.5 TARGET GROUP .............................................................................................................................................................. 9 1.6 HEALTH CARE LEVELS ................................................................................................................................................. 9 2.0 DIAGNOSIS OF MALARIA ............................................................................................................................................. 9 2.1. CLINICAL DIAGNOSIS OF MALARIA ............................................................................................................................. 10 2.1.1 UNCOMPLICATED MALARIA ............................................................................................................................... 10 2.1.2 SEVERE MALARIA .................................................................................................................................................. 10 2.2 PARASITOLOGICAL DIAGNOSIS ............................................................................................................................... 11 3.0 MANAGEMENT OF UNCOMPLICATED MALARIA ................................................................................................. 11 3.1 CASE DEFINITION ......................................................................................................................................................... 11 3.2. TREATMENT OBJECTIVES ............................................................................................................................................... 12 3.3. TREATMENT RECOMMENDATIONS ............................................................................................................................ 12 3.3.1 FIRST LINE TREATMENT: .......................................................................................................................................... 12 3.3.2 RECURRENT FALCIPARUM MALARIA .................................................................................................................... 14 Treatment Failure .......................................................................................................................................................................... 14 3.3.3 SUPPORTIVE TREATMENT ........................................................................................................................................ 14 3.3.4 CRITERIA FOR REFERRAL .................................................................................................................................... 16 4.0 MANAGEMENT OF SEVERE MALARIA .................................................................................................................... 16 4.1 CASE DEFINITION ............................................................................................................................................................... 17 4.2 TREATMENT OBJECTIVES .............................................................................................................................................. 17 4.3 TREATMENT RECOMMENDATIONS ............................................................................................................................... 17 4.4.1 Initial emergency treatment ......................................................................................................................................... 18 4.4.2. SPECIFIC ANTIMALARIAL TREATMENT ............................................................................................................... 19 5.0 TREATMENT OF MALARIA CAUSED BY OTHER SPECIES ......................................................................................... 20 6.0 DISEASE MANAGEMENT AT THE DIFFERENT LEVELS ............................................................................................. 20 6.1 MANAGEMENT OF UNCOMPLICATED MALARIA AT THE DIFFERENT LEVELS .................................................. 20 6.1.1 Community level .............................................................................................................................................................. 20 6.1.2 Management of uncomplicated malaria at the Maternal and Child Health Post (MCHP) ............................................... 21 6.1.3 Management of uncomplicated malaria at the Community Health Post (CHP) ............................................................... 21 6.1.4 Management of uncomplicated malaria at the Community Health Centre (CHC)........................................................... 21 6.1.5 Management of uncomplicated malaria in hospital ......................................................................................................... 21 6.2 Management of Severe Malaria at Different Levels ............................................................................................................... 21 6.2.1 Community level .............................................................................................................................................................. 21 6.2.2 Management of severe malaria at the Maternal and Child Health Post (MCHP) ............................................................ 22 6.2.3 Management of Severe malaria at the Community Health Post (CHP) ........................................................................... 22 6.2.4 Management of Severe malaria at the Community Health Centers (CHC)...................................................................... 22 6.2.5 Management of severe malaria at Hospital .................................................................................................................... 22 7.0 MALARIA CHEMPROPHYLAXIS ................................................................................................................................. 23 7.1 CHEMOPROPHYLAXIS FOR NON-IMMUNE VISITORS .......................................................................................... 23 7.3 ANNEXES .................................................................................................................................................................................. 24 List of Tables Table 1:Therapeutic efficacy of artesunate+amodiaquine in four sites and artemether+lumefantrine in four sites, Sierra Leone. PCR corrected responses. .................................................................................................................................... 8 Table 2:Therapeutic efficacy of artesunate + amodiaquine in two sites and artemether+lumefantrine in two sites, Sierra Leone. PCR uncorrected responses. .............................................................................................................................................. 8 Table 3: Clinical features of uncomplicated and Severe malaria ............................................................................................... 10 Table 4: Dosage schedule for fixed combination of ASAQ treatment ........................................................................................... 13 Table 5: Treatment schedule for Paracetamol tablets 500mg ......................................................................................................... 15 Table 6 : PARACETAMOL SYRUP 125mg/5ml. ....................................................................................................................... 15 Table 7: NUMBER OF PARACETAMOL TABLETS 100MG. ................................................................................................. 15 Table 8: Treatment schedule for Acetylsalicylic acid tablets 300mg (Aspirin tablets) .................................................................. 16 4 | P a g e List of Boxes Box 1: Initial Management of Severe Malaria .................................................................................................................................. 18 Box 2: Parenteral Artesunate dosage schedule ................................................................................................................................. 19 Box 3: Treatment using parenteral Artemether ...............................................................................................................................
Load more

Recommended publications
  • The Tarsal Taste of Honey Bees: Behavioral and Electrophysiological Analyses
    ORIGINAL RESEARCH ARTICLE published: 04 February 2014 BEHAVIORAL NEUROSCIENCE doi: 10.3389/fnbeh.2014.00025 The tarsal taste of honey bees: behavioral and electrophysiological analyses Maria Gabriela de Brito Sanchez 1,2*, Esther Lorenzo 1,2, Songkun Su 3, Fanglin Liu 4,YiZhan3 and Martin Giurfa 1,2 1 Centre National de la Recherche Scientifique (CNRS), Research Center on Animal Cognition (UMR5169), Toulouse, France 2 University Paul-Sabatier, Research Center on Animal Cognition (UMR5169), Toulouse, France 3 College of Animal Sciences, Zhejiang University, Hangzhou, China 4 Xishuangbanna Tropical Botanical Garden, Chinese Academy of Sciences, Kunming, China Edited by: Taste plays a crucial role in the life of honey bees as their survival depends on the Carmen Sandi, Ecole Polytechnique collection and intake of nectar and pollen, and other natural products. Here we studied Federale De Lausanne, Switzerland the tarsal taste of honey bees through a series of behavioral and electrophysiological Reviewed by: analyses. We characterized responsiveness to various sweet, salty and bitter tastants Judith Reinhard, University of Queensland, Australia delivered to gustatory sensilla of the fore tarsi. Behavioral experiments showed that Fernando J. Guerrieri, Univesité stimulation of opposite fore tarsi with sucrose and bitter substances or water yielded François Rabelais Tours, France different outcomes depending on the stimulation sequence. When sucrose was applied *Correspondence: first, thereby eliciting proboscis extension, no bitter substance could induce proboscis Maria Gabriela de Brito Sanchez, retraction, thus suggesting that the primacy of sucrose stimulation induced a central Centre de Recherches sur la Cognition Animale, Building 4R3, excitatory state. When bitter substances or water were applied first, sucrose stimulation Université de Toulouse, 31062 could still elicit proboscis extension but to a lower level, thus suggesting central inhibition Toulouse Cedex 9, France based on contradictory gustatory input on opposite tarsi.
    [Show full text]
  • Serious Risks Associated with Using Quinine to Prevent Or Treat Nocturnal Leg Cramps
    Serious risks associated with using Quinine to prevent or treat nocturnal leg cramps Quinine is FDA-approved for the label indications relating to leg ceived a dispensed prescription treatment of uncomplicated cramps and muscle pain.1 for quinine from U.S. outpatient Plasmodium falciparum malaria. Since 2006, there have been a retail pharmacies. In contrast, an It is not considered safe and ef- number of efforts to educate estimated 206,000 patients re- fective for the treatment or healthcare professionals about ceived a dispensed prescription prevention of leg cramps-- an these serious risks. These efforts for quinine in 2008.2 Cumula- "off-label" (non-FDA-approved) include labeling changes, adding tively from 2008 to 2011, use. Quinine is associated with general practice/family medi- serious and life-threatening ad- cine/doctor of osteopathy verse events, including specialties and internal medicine thrombocytopenia, specialties prescribed the major- hypersensitivity reac- ity of dispensed prescriptions for 3 tions, and quinine. Although use has de- QT prolongation. clined, the FDA remains concerned because the majority Thrombocytopenia associated of quinine use is associated with with the use of quinine for the off-label indications relating to treatment or prevention of leg leg cramps and muscle pain, and cramps includes serious adverse events continue immune thrombocyto- a boxed warning regarding he- to be reported. penic purpura matologic events associated with hemolytic uremic syn- off-label use of quinine, and The agency will continue to drome FDA and pharmaceutical indus- monitor quinine use and remind thrombotic thrombocyto- try communications. healthcare professionals about penic purpura with the serious risks associated with associated renal insuffi- Despite these efforts, awareness quinine in the preven- ciency.
    [Show full text]
  • Physical Composition, Proximate, Phytochemical and Impact of Coconut Oil on Lipid Profile of Albino Rats
    IOSR Journal of Applied Chemistry (IOSR-JAC) e-ISSN: 2278-5736.Volume 13, Issue 7 Ser. I (July. 2020), PP 51-56 www.iosrjournals.org Physical Composition, Proximate, Phytochemical and Impact of Coconut Oil on Lipid Profile of Albino Rats Boisa .N1, Nwachoko .N2, Bull .O.S1 and James .F.A1 1(Department of Chemistry, Rivers State University,Nkpolu-Oroworokwu, Port Harcourt, Nigeria) 2(Department of Biochemistry, Rivers State University,Nkpolu-Oroworokwu, Port Harcourt, Nigeria) Abstract: Background: Coconut oil is a food supplement derived from the Cocos nucifera L of Cocoideae subfamily and Arecaceae family, the oil is obtained from coconut kernel and it is anatural functional oil. This study was undertaken to evaluate the physical, proximate, phytochemical composition and the effect of coconut oil on lipid profile indices of albino rats. Materials and Methods:The proximate analysis was according to AOCS, phytochemical analysis was carried out with GC-FID.Thirty-five (35) albino rats were used for the lipid profile evaluation. Two phases of experiment with four (4) groups of male albino rats comprising of five (5) animals each, averagely weighing 180g-200g were employed. Phase 1 of the experiment was treated with coconut oil supplemented diet, where rodent chow was mixed with coconut oil while phase 2 experimental animals were treated with coconut oil by oral gavage. Group 1 served as the control for both phases while group 2, 3 and 4 were treated with 3ml/kg, 6ml/kg and 12ml/kg of coconut oil respectively for 4weeks. Results: The physical examination of the samples showed that the appearance of hot press method of extraction of coconut oil is pale-yellow while the oil from cold press method of extraction is colourless.
    [Show full text]
  • Special Forest Product Markets in the Pacific Northwest with Global Implications
    Chapter 3 Special forest product markets in the Pacific Northwest with global implications Keith A. Blatner Associate Professor Department of Natural Resource Sciences Washington State University Pullman, WA 99164-6410 would like to first give credit to my colleague who has worked with me I on many of these projects. Bill Schlosser was my former graduate student at the University of Idaho. He is now at Michigan State University and shortly will be a USAID employee in Khabarovsk in the Russian Far East. He and I researched special forest products together for about 6 or 7 years. In the course of today’s presentation, I’m going to focus primarily on products from the Pacific Northwest—major products, their markets, and economic contribution. However, I’m going to digress at various times to show the international flavor of this market. There is a growing industry on the eastside of the Cascades, where I work. In fact, many of the products that are harvested on the eastside currently are marketed and processed through westside processors, a phenomenon that is slowly changing. There are large international markets for a variety of products. The special forest products industry consists of several specialized industries. The floral greens industry uses wild-harvested evergreen plant materials in floral arrangements. Typically, these plants are flexible and have long-lasting properties so they can be used in fresh or dried arrangements, often as background material. Moss is used as covering for the base of arrangements, or in pots or baskets. Christmas ornamentals are bough products, primarily cones, that are used in Christmas wreaths, swags, and door charms.
    [Show full text]
  • Developments in Taste-Masking Techniques for Traditional Chinese Medicines
    pharmaceutics Review Developments in Taste-Masking Techniques for Traditional Chinese Medicines Xiao Zheng 1,2, Fei Wu 1,2,*, Yanlong Hong 2, Lan Shen 1, Xiao Lin 1,* and Yi Feng 2 1 College of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; [email protected] (X.Z.); [email protected] (L.S.) 2 Engineering Research Center of Modern Preparation Technology of TCM of Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; [email protected] (Y.H.); [email protected] (Y.F.) * Correspondence: [email protected] (F.W.); [email protected] (X.L.); Tel./Fax: +86-21-5132-2429 (F.W.); +86-21-5132-2197 (X.L.) Received: 30 July 2018; Accepted: 8 September 2018; Published: 12 September 2018 Abstract: A variety of pharmacologically active substances, including chemotherapeutic drugs and the substances from traditional Chinese medicine (TCM), always exhibit potent bioactivities after oral administration. However, their unpleasant taste (such as bitterness) and/or odor always decrease patient compliance and thus compromise their curative efficacies in clinical application. Therefore, the developments of taste-masking techniques are of great significance in improving their organoleptic properties. However, though a variety of taste-masking techniques have been successfully used to mask the unpalatable taste of chemotherapeutic drugs, their suitability for TCM substances is relatively limited. This is mainly due to the fact that the bitter ingredients existing in multicomponent TCM systems (i.e., effective fractions, single Chinese herbs, and compound preparations) are always unclear, and thus, there is lack of tailor-made taste-masking techniques to be utilized to conceal their unpleasant taste.
    [Show full text]
  • 27 CFR Ch. I (4–1–97 Edition)
    § 21.63 27 CFR Ch. I (4±1±97 Edition) 349. Miscellaneous drug processing (includ- 410. Disinfectants, insecticides, fungicides, ing manufacture of pills). and other biocides. 358. Processing miscellaneous chemicals. 430. Sterilizing and preserving solutions. 359. Processing miscellaneous products. 470. Theater sprays, incense, and room de- odorants. (2) As a raw material: (2) Miscellaneous uses: 511. Vinegar. 512. Acetic acid. 812. Product development and pilot plant 521. Ethyl acetate. uses (own use only). 523. Other ethyl esters. 590. Synthetic resins. § 21.65 Formula No. 38±B. 910. Animal feed supplements. (a) Formula. To every 100 gallons of (3) Miscellaneous uses: alcohol add: 812. Product development and pilot plant Ten pounds of any one, or a total of 10 uses (own use only). pounds of two or more, of the oils and sub- stances listed below: § 21.63 Formula No. 36. Anethole, N.F. Anise oil, N.F. (a) Formula. To every 100 gallons of Bay oil (myrcia oil), N.F. XI. alcohol add: Benzaldehyde, N.F. Three gallons of ammonia, aqueous, 27 to Bergamot oil, N.F. XI. 30 percent by weight; 3 gallons of strong am- Bitter almond oil, N.F. X. monia solution, N.F.: 17.5 pounds of caustic Camphor, U.S.P. soda, liquid grade, containing 50 percent so- Cedar leaf oil, U.S.P. XIII. dium hydroxide by weight; or 12.0 pounds of Chlorothymol, N.F. XII. caustic soda, liquid grade, containing 73 per- Cinnamic aldehyde, N.F. IX. Cinnamon oil, N.F. cent sodium hydroxide by weight. Citronella oil, natural. (b) Authorized uses.
    [Show full text]
  • Title Studies on Separation Method Using the Interactions Between
    Studies on Separation Method Using the Interactions between Title Cinchona Alkaloids and Optical Isomers( Dissertation_全文 ) Author(s) Tsurubou, Shigekazu Citation 京都大学 Issue Date 1991-03-23 URL https://doi.org/10.11501/3053039 本文は出版社の公開条件により公開していない部分があ Right ります Type Thesis or Dissertation Textversion author Kyoto University Analytica ChimicaActa, 215 (1988) 119-129 119 Elsevier Science Publishers B.V., Amsterdam- Printed in The Netherlands ION-PAIR EXTRACTION OF SOME CINCHONA ALKALOIDS WITH VARIOUS CHIRAL ORGANIC ANIONS SHIGEKAZU TSURUBOU '.Department of Chemistry, School of Liberal Arts, Asahi University, Hozumi-cho, Gifu 501 -02 ,~(Japan) ~; (Received 2nd March 1988) ,..... 'i 2 Studies on the Solvent Extraction of the Chiral Ion-pair between Some Cinchona Alkaloids and Acid Derivertives of Camphor Shigekazu TSURUBOU Department of Chemistry, School of Liberal Arts, ~sahi University , Hozumi- cho , Gifu 501-02 Two pairs of cinchona alkaloids, the quinine/quinidine and cinchonine/cinchonidine , are extracted by ion-pair formation with some anions of camphor derivertives . The extraction behaviours are examined , and the differences between the two isomers are compared . These alkaloids are extracted into chloroform and 1,2-dichloroethane in the pH range 4 - 7 as the 1:1 ion-pair with the chiral anions . The relationship between the distribution ratio of the ion-pair and pll is discussed . In the pH range between the pKal and pKa2 values of cinchona alkaloids, the extraction constants are determined, and the differ­ ences caused by the effect of substituents of cinchona alkaloids and counter ions are examined. The solvent effect are also studied. Keywords Stereoselectivity, cinchona alkaloid, acid derivertive of camphor, chiral ion-pair - 1 - Several investigations for the optical resolution confirmed that the differences of the log D values of isomers have been reported by usi~g gas and liquid obtained by the ion-pair extraction between cinchona 1 4 c h roma t ograp h lC.
    [Show full text]
  • Corrosion Inhibition of Henna Extract on Carbon Steel with Hybrid Coating TMSM-PMMA in HCL Solution
    Open Journal of Synthesis Theory and Applications, 2018, 7, 1-16 http://www.scirp.org/journal/ojsta ISSN Online: 2168-1252 ISSN Print: 2168-1244 Corrosion Inhibition of Henna Extract on Carbon Steel with Hybrid Coating TMSM-PMMA in HCL Solution Zahra Khoshkhou, Maryam Torkghashghaei*, Amin Rabiei Baboukani Advanced Materials Research Center, Materials Engineering Department, Najafabad Branch, Islamic Azad University, Najafabad, Iran How to cite this paper: Khoshkhou, Z., Abstract Torkghashghaei, M. and Baboukani, A.R. (2018) Corrosion Inhibition of Henna Green inhibitors are promising alternatives to toxic corrosion inhibitors as Extract on Carbon Steel with Hybrid Coat- they are environmentally safe substances, ecologically acceptable and renewa- ing TMSM-PMMA in HCL Solution. Open ble. In this research, the effect of green henna as an inhibitor existing in the Journal of Synthesis Theory and Applica- tions, 7, 1-16. coating of TMSM-PMMA and its electrochemical study were analyzed. The https://doi.org/10.4236/ojsta.2018.71001 coating was produced by “sol-gel” method in order to protect the corrosion of low-carbon steel. TMSM hybrid cell was synthesized by hydrolysis and con- Received: January 10, 2018 densation, Metaacryloxypropyltrimethoxysilane and Tetraetylorthosilicate Accepted: January 28, 2018 Published: January 31, 2018 with 1:1 molar ratio and PMMA hybrid cell was produced by Methylmetaa- crylate polymerization. Finally two cells were mixed in 1:1 weight ratio. The Copyright © 2018 by authors and carbon steel substrates were prepared by dip coating method. SEM technique Scientific Research Publishing Inc. was applied for the microstructure evaluation of thin layers including differ- This work is licensed under the Creative Commons Attribution International ent concentrations of henna extract.
    [Show full text]
  • Determining Effects of Areca (Betel) Nut Chewing in a Prospective Cohort
    Ome-Kaius et al. BMC Pregnancy and Childbirth (2015) 15:177 DOI 10.1186/s12884-015-0615-z RESEARCH ARTICLE Open Access Determining effects of areca (betel) nut chewing in a prospective cohort of pregnant women in Madang Province, Papua New Guinea Maria Ome-Kaius1*, Holger W Unger2, Dupain Singirok1, Regina A Wangnapi1, Sarah Hanieh1, Alexandra J Umbers1, Julie Elizah1, Peter Siba1, Ivo Mueller3,4 and Stephen J Rogerson2 Abstract Background: Chewing areca nut (AN), also known as betel nut, is common in Asia and the South Pacific and the habit has been linked to a number of serious health problems including oral cancer. Use of AN in pregnancy has been associated with a reduction in mean birthweight in some studies, but this association and the relationship between AN chewing and other adverse pregnancy outcomes remain poorly understood. Methods: We assessed the impact of AN chewing on adverse outcomes including stillbirth, low birthweight (LBW, <2,500 g) and anaemia at delivery (haemoglobin <11.0 g/dL) in a longitudinal cohort of 2,700 pregnant women residing in rural lowland Papua New Guinea (PNG) from November 2009 until February 2013. Chewing habits and participant characteristics were evaluated at first antenatal visit and women were followed until delivery. Results: 83.3 % [2249/2700] of pregnant women used AN, and most chewed on a daily basis (86.2 % [1939/2249]. Smoking and alcohol use was reported by 18.9 % (511/2700) and 5.0 % (135/2688) of women, respectively. AN use was not associated with pregnancy loss or congenital abnormalities amongst women with a known pregnancy outcome (n = 2215).
    [Show full text]
  • The Columbian Exchange: a History of Disease, Food, and Ideas
    Journal of Economic Perspectives—Volume 24, Number 2—Spring 2010—Pages 163–188 The Columbian Exchange: A History of Disease, Food, and Ideas Nathan Nunn and Nancy Qian hhee CColumbianolumbian ExchangeExchange refersrefers toto thethe exchangeexchange ofof diseases,diseases, ideas,ideas, foodfood ccrops,rops, aandnd populationspopulations betweenbetween thethe NewNew WorldWorld andand thethe OldOld WWorldorld T ffollowingollowing thethe voyagevoyage ttoo tthehe AAmericasmericas bbyy ChristoChristo ppherher CColumbusolumbus inin 1492.1492. TThehe OldOld WWorld—byorld—by wwhichhich wwee mmeanean nnotot jjustust EEurope,urope, bbutut tthehe eentirentire EEasternastern HHemisphere—gainedemisphere—gained fromfrom tthehe CColumbianolumbian EExchangexchange iinn a nnumberumber ooff wways.ays. DDiscov-iscov- eeriesries ooff nnewew ssuppliesupplies ofof metalsmetals areare perhapsperhaps thethe bestbest kknown.nown. BButut thethe OldOld WWorldorld aalsolso ggainedained newnew staplestaple ccrops,rops, ssuchuch asas potatoes,potatoes, sweetsweet potatoes,potatoes, maize,maize, andand cassava.cassava. LessLess ccalorie-intensivealorie-intensive ffoods,oods, suchsuch asas tomatoes,tomatoes, chilichili peppers,peppers, cacao,cacao, peanuts,peanuts, andand pineap-pineap- pplesles wwereere aalsolso iintroduced,ntroduced, andand areare nownow culinaryculinary centerpiecescenterpieces inin manymany OldOld WorldWorld ccountries,ountries, namelynamely IItaly,taly, GGreece,reece, andand otherother MediterraneanMediterranean countriescountries (tomatoes),(tomatoes),
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • Volume 73 – No. 2
    Volume 73 Number 2 November 2013 Journal of the Association of Food and Drug Officials Serving the regulatory community since January 1937 Contents of this Issue Page From The Executive Director ............................................................................... 1 2013-2014 AFDO Board of Directors ................................................................... 3 2013-2014 AFDO Board-Appointed Advisors ....................................................... 3 2013-2014 AFDO Committee Chairpersons ......................................................... 4 AFDO Regional Affiliates ...................................................................................... 5 2013 AFDO Award Recipients .............................................................................. 6 2012 AFDO Resolutions ....................................................................................... 7 About the Authors ............................................................................................. 14 President’s Address............................................................................................ 17 Glenn W. Kilpatrick Address ............................................................................... 21 FDA Keynote ...................................................................................................... 25 Health Canada Keynote ..................................................................................... 33 CFIA Keynote .....................................................................................................
    [Show full text]